Literature DB >> 27125368

Pooled influenza vaccine effectiveness estimates for Australia, 2012-2014.

S G Sullivan1, K S Carville2, M Chilver3, J E Fielding4, K A Grant2, H Kelly4, A Levy5, N P Stocks3, S S Tempone5, A K Regan6.   

Abstract

Data were pooled from three Australian sentinel general practice influenza surveillance networks to estimate Australia-wide influenza vaccine coverage and effectiveness against community presentations for laboratory-confirmed influenza for the 2012, 2013 and 2014 seasons. Patients presenting with influenza-like illness at participating GP practices were swabbed and tested for influenza. The vaccination odds of patients testing positive were compared with patients testing negative to estimate influenza vaccine effectiveness (VE) by logistic regression, adjusting for age group, week of presentation and network. Pooling of data across Australia increased the sample size for estimation from a minimum of 684 to 3,683 in 2012, from 314 to 2,042 in 2013 and from 497 to 3,074 in 2014. Overall VE was 38% [95% confidence interval (CI) 24-49] in 2012, 60% (95% CI 45-70) in 2013 and 44% (95% CI 31-55) in 2014. For A(H1N1)pdm09 VE was 54% (95% CI-28 to 83) in 2012, 59% (95% CI 33-74) in 2013 and 55% (95% CI 39-67) in 2014. For A(H3N2), VE was 30% (95% CI 14-44) in 2012, 67% (95% CI 39-82) in 2013 and 26% (95% CI 1-45) in 2014. For influenza B, VE was stable across years at 56% (95% CI 37-70) in 2012, 57% (95% CI 30-73) in 2013 and 54% (95% CI 21-73) in 2014. Overall VE against influenza was low in 2012 and 2014 when A(H3N2) was the dominant strain and the vaccine was poorly matched. In contrast, overall VE was higher in 2013 when A(H1N1)pdm09 dominated and the vaccine was a better match. Pooling data can increase the sample available and enable more precise subtype- and age group-specific estimates, but limitations remain.

Entities:  

Keywords:  Influenza; influenza season; influenza vaccine; influenza-like illness; vaccine effectiveness

Mesh:

Substances:

Year:  2016        PMID: 27125368      PMCID: PMC9150515          DOI: 10.1017/S0950268816000819

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  59 in total

1.  "I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9.

Authors:  E Kissling; M Valenciano; Jm Falcao; A Larrauri; K Widgren; D Pitigoi; B Oroszi; B Nunes; C Savulescu; A Mazick; E Lupulescu; B Ciancio; A Moren
Journal:  Euro Surveill       Date:  2009-11-05

2.  Surveillance systems reported in CDI, 2011.

Authors: 
Journal:  Commun Dis Intell Q Rep       Date:  2011-03

3.  Adverse events associated with 2010 CSL and other inactivated influenza vaccines.

Authors:  Heath A Kelly; Danuta M Skowronski; Gaston De Serres; Paul V Effler
Journal:  Med J Aust       Date:  2011-09-19       Impact factor: 7.738

4.  Moderate influenza vaccine effectiveness in Victoria, Australia, 2011.

Authors:  J E Fielding; K A Grant; T Tran; H A Kelly
Journal:  Euro Surveill       Date:  2012-03-15

5.  The underrecognized burden of influenza in young children.

Authors:  Katherine A Poehling; Kathryn M Edwards; Geoffrey A Weinberg; Peter Szilagyi; Mary Allen Staat; Marika K Iwane; Carolyn B Bridges; Carlos G Grijalva; Yuwei Zhu; David I Bernstein; Guillermo Herrera; Dean Erdman; Caroline B Hall; Ranee Seither; Marie R Griffin
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

6.  Influenza vaccine effectiveness against laboratory confirmed influenza in Greece during the 2013-2014 season: a test-negative study.

Authors:  Theodore Lytras; Athanasios Kossyvakis; Angeliki Melidou; Maria Exindari; Georgia Gioula; Vasiliki Pogka; Nikolaos Malisiovas; Andreas Mentis
Journal:  Vaccine       Date:  2014-11-18       Impact factor: 3.641

7.  Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.

Authors:  D M Skowronski; C Masaro; T L Kwindt; A Mak; M Petric; Y Li; R Sebastian; M Chong; T Tam; G De Serres
Journal:  Vaccine       Date:  2006-10-16       Impact factor: 3.641

8.  The epidemiology of hospitalized influenza in children, a two year population-based study in the People's Republic of China.

Authors:  Wei Ji; Tao Zhang; Xuelan Zhang; Lufang Jiang; Yunfang Ding; Chuangli Hao; Liwen Ju; Yuqing Wang; Qingwu Jiang; Mark Steinhoff; Steven Black; Genming Zhao
Journal:  BMC Health Serv Res       Date:  2010-03-30       Impact factor: 2.655

9.  Influenza vaccine effectiveness estimates for Western Australia during a period of vaccine and virus strain stability, 2010 to 2012.

Authors:  Avram Levy; Sheena G Sullivan; Simone S Tempone; Kerry L M Wong; Annette K Regan; Gary K Dowse; Paul V Effler; David W Smith
Journal:  Vaccine       Date:  2014-09-16       Impact factor: 3.641

10.  Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.

Authors:  Danuta M Skowronski; Naveed Z Janjua; Gaston De Serres; Suzana Sabaiduc; Alireza Eshaghi; James A Dickinson; Kevin Fonseca; Anne-Luise Winter; Jonathan B Gubbay; Mel Krajden; Martin Petric; Hugues Charest; Nathalie Bastien; Trijntje L Kwindt; Salaheddin M Mahmud; Paul Van Caeseele; Yan Li
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more
  8 in total

1.  The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.

Authors:  Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling
Journal:  Epidemiology       Date:  2020-01       Impact factor: 4.822

2.  Association between Haemagglutination inhibiting antibodies and protection against clade 6B viruses in 2013 and 2015.

Authors:  Sophia Ng; Saira Saborio; Guillermina Kuan; Lionel Gresh; Nery Sanchez; Sergio Ojeda; Eva Harris; Angel Balmaseda; Aubree Gordon
Journal:  Vaccine       Date:  2017-10-03       Impact factor: 3.641

3.  Epidemiology of viral respiratory infections in Australian working-age adults (20-64 years): 2010-2013.

Authors:  B M Varghese; E Dent; M Chilver; S Cameron; N P Stocks
Journal:  Epidemiol Infect       Date:  2018-02-21       Impact factor: 4.434

4.  Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016.

Authors:  A Möhl; L Gräfe; C Helmeke; D Ziehm; M Monazahian; H-M Irmscher; J Dreesman
Journal:  Epidemiol Infect       Date:  2017-12-06       Impact factor: 4.434

5.  Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017.

Authors:  Sheena G Sullivan; Monique B Chilver; Kylie S Carville; Yi-Mo Deng; Kristina A Grant; Geoff Higgins; Naomi Komadina; Vivian Ky Leung; Cara A Minney-Smith; Don Teng; Thomas Tran; Nigel Stocks; James E Fielding
Journal:  Euro Surveill       Date:  2017-10

6.  Estimating Vaccine-Driven Selection in Seasonal Influenza.

Authors:  Frank T Wen; Sidney M Bell; Trevor Bedford; Sarah Cobey
Journal:  Viruses       Date:  2018-09-18       Impact factor: 5.048

7.  Emergency Department demand associated with seasonal influenza, 2010 through 2014, New South Wales, Australia.

Authors:  David J Muscatello; Kendall J Bein; Michael M Dinh
Journal:  Western Pac Surveill Response J       Date:  2017-09-25

Review 8.  Subtype H3N2 Influenza A Viruses: An Unmet Challenge in the Western Pacific.

Authors:  Min Kang; Mark Zanin; Sook-San Wong
Journal:  Vaccines (Basel)       Date:  2022-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.